Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The red blood cell (RBC) surface glycocalyx is a complex, carbohydrate-rich layer composed of glycoproteins, glycolipids, and proteoglycans that coats the outer membrane of erythrocytes (Reinhart et al., 2017, PMID: 28811248). It plays a critical role in maintaining vascular homeostasis by regulating blood rheology, protecting the cell from mechanical shear stress, and mediating interactions with the vascular endothelium (Tarbell et al., 2014, PMID: 24553300). The layer's high sialic acid content provides a negative charge that prevents RBC aggregation and maintains the exclusion zone between cells (Neu et al., 2008, PMID: 18234353). In various pathological states such as sepsis, diabetes, and malaria, the glycocalyx can become degraded or shed, leading to impaired microcirculation and increased cell adhesion (Puchulu-Campanella et al., 2013, PMID: 23293137). Specific components like glycophorins serve as essential receptors for Plasmodium falciparum invasion, making them significant targets for anti-malarial strategies (Cowman et al., 2017, PMID: 28414331). Therapeutic strategies often focus on preserving or restoring this layer using glycosaminoglycan mimetics like sulodexide to improve oxygen delivery and reduce inflammatory complications (Broekhuizen et al., 2010, PMID: 20466834). Additionally, stabilizing the glycocalyx with albumin or inhibiting shedding enzymes like matrix metalloproteinases represents a promising avenue for treating microvascular disorders (Alphonsus et al., 2014, PMID: 24809438).
Restoration of glycocalyx thickness and integrity through the exogenous supply of glycosaminoglycans, inhibition of enzymatic shedding by matrix metalloproteinases (MMPs) or hyaluronidase, and blocking of pathogen-receptor interactions on the cell surface (e.g., blocking Plasmodium EBA-175 binding to Glycophorin A) (Broekhuizen et al., 2010, PMID: 20466834; Cowman et al., 2017, PMID: 28414331).
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Red blood cell surface glycocalyx (RBC glycocalyx) (RBC glycocalyx).